
Global R&D Pipeline
My Favorite
Hot Targets:
ADGRG1
Back
Total number of drugs
4
Phase II and later clinical stages
0%
Involving companies
2
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10C7-Duo | 10C7-Duo | Antibody drug conjugate (ADC) ADC | Neoplasms Skin and Musculoskeletal Diseases | adhesion G protein-coupled receptor G1 inhibitors | UTHealth Houston | UTHealth Houston | Preclinical | 10C7-Duo | detail > | ||||||||||||
| 9E3-PBD | 9E3-PBD | Antibody drug conjugate (ADC) ADC | Neoplasms Skin and Musculoskeletal Diseases | adhesion G protein-coupled receptor G1 inhibitors | UTHealth Houston | UTHealth Houston | Preclinical | 9E3-PBD | detail > | ||||||||||||
| anti-GPR56-ADC(University of Texas Health Science Center At San Antonio) | anti-GPR56-ADC(University of Texas Health Science Center At San Antonio) | Biological products | Neoplasms Digestive System Disorders | adhesion G protein-coupled receptor G1 modulators | University of Texas Health Science Center At San Antonio | University of Texas Health Science Center At San Antonio | Preclinical | anti-GPR56-ADC(University of Texas Health Science Center At San Antonio) | detail > | ||||||||||||
| P7 Peptides | P7 Peptides | Peptides | Nervous System Diseases | adhesion G protein-coupled receptor G1 agonists | Preclinical | P7 Peptides | detail > |
Total 4 data
1


